Neratinib, fulvestrant, and eribulin for advanced breast cancer
Part of Cancer clinical trials.
This trial tests a combination of three drugs for advanced breast cancer that is both hormone-receptor-positive and HER2-positive, and has stopped responding to a newer targeted therapy called T-DXd. The goal is to see if this new combo can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have advanced breast cancer that is hormone-receptor-positive and HER2-positive.
- Your cancer has gotten worse or you could not tolerate prior treatment with T-DXd.
- You have had prior treatment with anthracycline and taxane chemotherapy.
- You have at least one measurable tumor, and your overall health is good enough (able to do light activity).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This Phase 2 study tests a genetically guided treatment plan for ER-positive breast cancer that has progressed after CDK4/6 therapy. It may help by matching treatment to tumor genetic changes.
This trial is testing a drug called eribulin (given alone or with other drugs) for people with advanced HER2-negative breast cancer that has already been treated with an ADC (antibody-drug conjugate). The goal is to see if this new treatment can help control the cancer and potentially shrink tumors.
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Hear when a new Brest Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.